Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab withdrawal in well-controlled severe asthma
2024-516789-13-00Phase 4Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dupilumab in severe asthma (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Strategy failure within 24 months. Planned start Dec 2025; status: authorised.
02
Drugs
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2024-516789-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516789-13-00.